COVALON TECHNOLOGIES LTD (COV.CA) Fundamental Analysis & Valuation

TSX-V:COV • CA22282D3022

Current stock price

1.97 CAD
+0.04 (+2.07%)
Last:

This COV.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. COV.CA Profitability Analysis

1.1 Basic Checks

  • In the past year COV was profitable.
  • COV had a positive operating cash flow in the past year.
  • In multiple years COV reported negative net income over the last 5 years.
  • In multiple years COV reported negative operating cash flow during the last 5 years.
COV.CA Yearly Net Income VS EBIT VS OCF VS FCFCOV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.98%, COV belongs to the top of the industry, outperforming 95.45% of the companies in the same industry.
  • COV has a better Return On Equity (3.70%) than 95.45% of its industry peers.
  • COV's Return On Invested Capital of 1.29% is amongst the best of the industry. COV outperforms 95.45% of its industry peers.
Industry RankSector Rank
ROA 2.98%
ROE 3.7%
ROIC 1.29%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.CA Yearly ROA, ROE, ROICCOV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • Looking at the Profit Margin, with a value of 3.10%, COV belongs to the top of the industry, outperforming 95.45% of the companies in the same industry.
  • The Operating Margin of COV (1.59%) is better than 95.45% of its industry peers.
  • COV has a Gross Margin of 52.27%. This is amongst the best in the industry. COV outperforms 86.36% of its industry peers.
  • COV's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.59%
PM (TTM) 3.1%
GM 52.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
COV.CA Yearly Profit, Operating, Gross MarginsCOV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. COV.CA Health Analysis

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for COV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COV.CA Yearly Shares OutstandingCOV.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2024 5M 10M 15M 20M 25M
COV.CA Yearly Total Debt VS Total AssetsCOV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M 40M

2.2 Solvency

  • COV has an Altman-Z score of 5.23. This indicates that COV is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.23, COV belongs to the top of the industry, outperforming 86.36% of the companies in the same industry.
  • The Debt to FCF ratio of COV is 0.32, which is an excellent value as it means it would take COV, only 0.32 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of COV (0.32) is better than 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that COV is not too dependend on debt financing.
  • COV's Debt to Equity ratio of 0.06 is fine compared to the rest of the industry. COV outperforms 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.32
Altman-Z 5.23
ROIC/WACC0.16
WACC8.16%
COV.CA Yearly LT Debt VS Equity VS FCFCOV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • COV has a Current Ratio of 5.69. This indicates that COV is financially healthy and has no problem in meeting its short term obligations.
  • COV has a better Current ratio (5.69) than 81.82% of its industry peers.
  • COV has a Quick Ratio of 4.29. This indicates that COV is financially healthy and has no problem in meeting its short term obligations.
  • COV's Quick ratio of 4.29 is amongst the best of the industry. COV outperforms 81.82% of its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 4.29
COV.CA Yearly Current Assets VS Current LiabilitesCOV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. COV.CA Growth Analysis

3.1 Past

  • COV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -82.26%.
  • Looking at the last year, COV shows a decrease in Revenue. The Revenue has decreased by -9.04% in the last year.
  • The Revenue has been growing by 19.43% on average over the past years. This is quite good.
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-9.04%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-15.64%

3.2 Future

  • COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.60% yearly.
  • The Revenue is expected to grow by 6.78% on average over the next years.
EPS Next Y3%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.6%
Revenue Next Year0.99%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.78%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COV.CA Yearly Revenue VS EstimatesCOV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
COV.CA Yearly EPS VS EstimatesCOV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

6

4. COV.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 65.67, COV can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, COV is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.91. COV is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 13.66 indicates a correct valuation of COV.
  • COV's Price/Forward Earnings ratio is rather cheap when compared to the industry. COV is cheaper than 86.36% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, COV is valued a bit cheaper.
Industry RankSector Rank
PE 65.67
Fwd PE 13.66
COV.CA Price Earnings VS Forward Price EarningsCOV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COV indicates a rather cheap valuation: COV is cheaper than 95.45% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, COV is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.32
EV/EBITDA 26.01
COV.CA Per share dataCOV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COV does not grow enough to justify the current Price/Earnings ratio.
  • COV has a very decent profitability rating, which may justify a higher PE ratio.
  • COV's earnings are expected to grow with 35.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)21.89
PEG (5Y)N/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. COV.CA Dividend Analysis

5.1 Amount

  • COV has a Yearly Dividend Yield of 8.20%, which is a nice return.
  • Compared to an average industry Dividend Yield of 0.48, COV pays a better dividend. On top of this COV pays more dividend than 100.00% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 8.2%

5.2 History

  • COV does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
COV.CA Yearly Dividends per shareCOV.CA Yearly Dividends per shareYearly Dividends per share 2025 0.05 0.1

5.3 Sustainability

DPN/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%
COV.CA Yearly Income VS Free CF VS DividendCOV.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

More info and screens

Find the best dividend stocksShow peers with best dividend

COV.CA Fundamentals: All Metrics, Ratios and Statistics

COVALON TECHNOLOGIES LTD

TSX-V:COV (4/8/2026, 7:00:00 PM)

1.97

+0.04 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.08%
Ins Owner ChangeN/A
Market Cap54.41M
Revenue(TTM)31.54M
Net Income(TTM)977.40K
Analysts84.44
Price Target2.96 (50.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 8.2%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.14%
Min EPS beat(2)-100%
Max EPS beat(2)124.27%
EPS beat(4)2
Avg EPS beat(4)4.61%
Min EPS beat(4)-100%
Max EPS beat(4)124.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.34%
Min Revenue beat(2)-25.15%
Max Revenue beat(2)-19.53%
Revenue beat(4)0
Avg Revenue beat(4)-15.41%
Min Revenue beat(4)-25.15%
Max Revenue beat(4)-3.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-41.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.33%
Valuation
Industry RankSector Rank
PE 65.67
Fwd PE 13.66
P/S 1.73
P/FCF 8.32
P/OCF 6.87
P/B 2.06
P/tB 2.17
EV/EBITDA 26.01
EPS(TTM)0.03
EY1.52%
EPS(NY)0.14
Fwd EY7.32%
FCF(TTM)0.24
FCFY12.03%
OCF(TTM)0.29
OCFY14.55%
SpS1.14
BVpS0.96
TBVpS0.91
PEG (NY)21.89
PEG (5Y)N/A
Graham Number0.8
Profitability
Industry RankSector Rank
ROA 2.98%
ROE 3.7%
ROCE 1.79%
ROIC 1.29%
ROICexc 3.59%
ROICexgc 4.14%
OM 1.59%
PM (TTM) 3.1%
GM 52.27%
FCFM 20.75%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
F-Score3
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.32
Debt/EBITDA 1.06
Cap/Depr 146.06%
Cap/Sales 4.35%
Interest Coverage 250
Cash Conversion 549.16%
Profit Quality 669.45%
Current Ratio 5.69
Quick Ratio 4.29
Altman-Z 5.23
F-Score3
WACC8.16%
ROIC/WACC0.16
Cap/Depr(3y)88.92%
Cap/Depr(5y)79.37%
Cap/Sales(3y)2.96%
Cap/Sales(5y)3.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y3%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.6%
Revenue 1Y (TTM)-9.04%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-15.64%
Revenue Next Year0.99%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.78%
EBIT growth 1Y-89.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year670.66%
EBIT Next 3Y139.18%
EBIT Next 5Y77.64%
FCF growth 1Y271.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y395.19%
OCF growth 3YN/A
OCF growth 5YN/A

COVALON TECHNOLOGIES LTD / COV.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVALON TECHNOLOGIES LTD?

ChartMill assigns a fundamental rating of 6 / 10 to COV.CA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 6 / 10 to COVALON TECHNOLOGIES LTD (COV.CA). This can be considered as Fairly Valued.


What is the profitability of COV stock?

COVALON TECHNOLOGIES LTD (COV.CA) has a profitability rating of 6 / 10.


Can you provide the financial health for COV stock?

The financial health rating of COVALON TECHNOLOGIES LTD (COV.CA) is 8 / 10.


What is the earnings growth outlook for COVALON TECHNOLOGIES LTD?

The Earnings per Share (EPS) of COVALON TECHNOLOGIES LTD (COV.CA) is expected to grow by 3% in the next year.